Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $4.00 price target on Context Therapeutics (NASDAQ: CNTX).

The analyst commented, "Context Therapeutics reported FY2025 financial results and narrowed guidance for the readout of the first-in-human (FiH) dose escalation data from its first two T cell engagers, which are now expected in June (CLDN6 x CD3) and September 2026 (MSLN x CD3). We hosted CNTX at the Citizens Life Sciences Conference in Miami in early March, where CEO Martin Lehr highlighted expectations for the two upcoming data readouts. We maintain our Market Outperform rating and risk-adjusted, DCF-derived, $4 price target ahead of important anticipated updates this year."

For an analyst ratings summary and ratings history on Context Therapeutics click here. For more ratings news on Context Therapeutics click here.

Shares of Context Therapeutics closed at $3.18 yesterday.